Clostridium Difficile Infection
131
8
8
75
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
40 trials with published results (31%)
Research Maturity
75 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
14.5%
19 terminated out of 131 trials
79.8%
-6.7% vs benchmark
24%
32 trials in Phase 3/4
53%
40 of 75 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 75 completed trials
Clinical Trials (131)
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
Fecal Microbiota Transplant
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
Fecal Microbiota Transplant National Registry
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Fecal Microbiota Transplantation for C Diff Infection
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
FQ Restriction for the Prevention of CDI
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Study on Clostridium Difficile Infection in Infants
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)